Video

Diagnosed With Liver Cancer? See a Specialist

Author(s):

Andrea J. Wilson

A liver cancer specialist can be very beneficial for those diagnosed.

It is important that patients with liver cancer see a doctor who specializes in the disease, according to Andrea J. Wilson, founder and president of Blue Faery: The Adrienne Wilson Liver Cancer Foundation.

General oncologists see many different cancers in their practice, and few, if any, may be liver cancers. Specialists may be better equipped to track changes in the liver cancer space, as well as new therapies that may be coming down the pipeline and clinical trials.

Related Videos
Image of bald man.
Dr. Tycel Phillips is an Associate Professor in the Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, at City of Hope in Duarte, California.
Image of Dr. Salani.
Dr. Debu Tripathy is a professor and chairman of the Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, in Houston, and the editor-in-chief of CURE®.
Dr. Suneel Kamath is an assistant professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, in Ohio.
Image of Dr. Fakih.
Dr. Catherine Wu is chief of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, and institute member at the Broad Institute of MIT and Harvard, in Boston, Massachusetts.
Dr. John Oertle discusses the key benefits to come from patients with cancer connecting with support networks, advocacy groups and resources.
Dr. Gabriel A. Brooks discussed the recent FDA product labeling update for Xeloda and 5-FU.
Dr. Alan Tan is the GU Oncology Lead at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee, as well as an associate professor in the Division of Hematology/Oncology at Vanderbilt University Medical Center and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Related Content
Image of man with black hair.
February 3rd 2025

Rybrevant Alone and in Combo With Chemo is Efficacious in Wildtype+ mCRC

Ryan Scott
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified metastatic colorectal cancer.
Marshall Morris, the founder of Dying Defiantly
December 8th 2022

Creating a Charity 8 Days After a Rare Cancer Diagnosis: Dying Defiantly Founder Shares His Story

Sailaja Darisipudi Andy Polhamus
After Marshall Morris was diagnosed with a rare cancer and given only six months to live, he created a charity that empowers people with terminal illness and provides them with counseling and support.
Illustration of the liver.
January 25th 2025

Opdivo Plus Yervoy May Improve Survival and Responses in Frontline uHCC

Jordyn Sava
Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in the CheckMate 9DW study.
Making Art From Cancer
December 10th 2020

Making Art From Cancer

Jessica Skarzynski
This week on the “CURE® Talks Cancer” podcast, we spoke with renowned street artist James Cochran about one of his art projects that was commissioned to symbolize the creativity and commitment of those who work tirelessly to eradicate cancer.
Image of man with brown hair.
January 11th 2025

A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval

Ryan Scott
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
Illustration of body, highlighting the liver.
January 7th 2025

Stereotactic Body Radiation May Improve Survival in Liver Cancer Subset

Spencer Feldman
Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in locally advanced hepatocellular carcinoma.